474700
Mevastatin
≥95% (HPLC), HMG-CoA reductase inhibitor, solid
别名:
Mevastatin, Compactin
Product Name
Mevastatin, An antibiotic that acts as a potent inhibitor of HMG-CoA reductase, thus suppressing Ras farnesylation.
质量水平
描述
Merck USA index - 14, 6164
方案
≥95% (HPLC)
表单
solid
制造商/商品名称
Calbiochem®
储存条件
OK to freeze
颜色
white
溶解性
ethanol: soluble
运输
ambient
储存温度
2-8°C
SMILES字符串
O1[C@@H](C[C@H](CC1=O)O)CC[C@@H]2[C@H]3[C@H](CCC=C3C=C[C@@H]2C)OC(=O)[C@H](CC)C
InChI
1S/C23H34O5/c1-4-14(2)23(26)28-20-7-5-6-16-9-8-15(3)19(22(16)20)11-10-18-12-17(24)13-21(25)27-18/h6,8-9,14-15,17-20,22,24H,4-5,7,10-13H2,1-3H3/t14-,15-,17+,18+,19-,20-,22-/m0/s1
InChI key
AJLFOPYRIVGYMJ-INTXDZFKSA-N
相关类别
一般描述
An antibiotic that acts as a potent inhibitor of HMG-CoA reductase, thus suppresses Ras farnesylation. Inhibitor of myoblast fusion. Causes cell cycle arrest in late G1 phase. May induce bone morphogenic protein-2 (BMP-2). This product requires activation for use in cell culture and cell-free assay systems. To activate, treat with ethanol solution with 1 N NaOH and then neutralize with 1 N HCl to pH 7.2 (see Keyomarsi, K . et al. 1991).
This is an inactive form which may require activation for use with isolated cells depending upon the application. To activate, treat with NaOH in ethanol and then neutralize to pH 7.2.
生化/生理作用
Cell permeable: no
Primary Target
HMG-CoA reductase
HMG-CoA reductase
Product does not compete with ATP.
Reversible: no
制备说明
Following reconstitution, aliquot and freeze (-20°C). Stock solutions are stable for up to 2 months at -20°C.
其他说明
Sugiyama, M., et al. 2000. Biochem. Biophys. Res. Commun.271, 688.
Hug, T., et al. 1995. Pflugers Archiv. Eur. J. Physiol.429, 682.
Belo, R.S., et al. 1993. Mol.Cell. Biochem.126, 159.
McLeish, K.R., et al. 1993. Biochem. Biophys. Res. Commun.197, 763.
Keyomarsi, K., et al. 1991. Cancer Res. 51, 3602.
Jackson, J.H., et al. 1990. Proc. Natl. Acad. Sci. USA 87, 3042.
Kita, T., et al. 1980. J. Clin. Invest. 66, 1094.
Hug, T., et al. 1995. Pflugers Archiv. Eur. J. Physiol.429, 682.
Belo, R.S., et al. 1993. Mol.Cell. Biochem.126, 159.
McLeish, K.R., et al. 1993. Biochem. Biophys. Res. Commun.197, 763.
Keyomarsi, K., et al. 1991. Cancer Res. 51, 3602.
Jackson, J.H., et al. 1990. Proc. Natl. Acad. Sci. USA 87, 3042.
Kita, T., et al. 1980. J. Clin. Invest. 66, 1094.
法律信息
CALBIOCHEM is a registered trademark of Merck KGaA, Darmstadt, Germany
免责声明
Toxicity: Standard Handling (A)
储存分类代码
11 - Combustible Solids
WGK
WGK 3
闪点(°F)
Not applicable
闪点(°C)
Not applicable
Ryuichi Nakahara et al.
The EMBO journal, 42(22), e114032-e114032 (2023-10-02)
Bone marrow-derived cells (BMDCs) infiltrate hypoxic tumors at a pre-angiogenic state and differentiate into mature macrophages, thereby inducing pro-tumorigenic immunity. A critical factor regulating this differentiation is activation of SREBP2-a well-known transcription factor participating in tumorigenesis progression-through unknown cellular mechanisms.
我们的科学家团队拥有各种研究领域经验,包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.
联系客户支持